Cerebral Blood Flow Effects of Resveratrol and Piperine in Humans

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Dietary Supplement: Trans- resveratrol; Other: Placebo (silica)

• Registration Number: NCT01331382
• Lead Sponsor: Northumbria University

Brief Summary

Resveratrol is associated with a plethora of physiological effects in humans, including modulation of cerebral blood flow, despite apparently poor bioavailability. This study investigated whether the physiological effects of resveratrol could be affected when co-supplemented with piperine, an alkaloid which may be able to enhance the bioavailability of resveratrol.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04
• Primary Completion: 2010-11
• Study Completion: 2010-11
• Status Verified: 2011-04
• Study First Submitted: 2011-04-06
• Study First Submitted QC: 2011-04-07
• Last Update Submitted: 2011-04-07
• Study First Posted: 2011-04-08
• Last Update Posted: 2011-04-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 23

Inclusion Criteria

• Between the ages of 18-35 years old
• Healthy
• Non-smoker

Exclusion Criteria

• Not proficient in English
• Taking medication or herbal supplements
• Pregnant or breast feeding
• Heavy caffeine consumer
• History of head trauma, migraines, learning difficulties, ADHD, gastrointestinal problems.
• Food allergies of intolerances

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
250mg trans- resveratrol	Trans- resveratrol	-
250mg trans- resveratrol	Placebo (silica)	-
250mg trans-resveratrol with 20mg piperine	Trans- resveratrol	-
250mg trans-resveratrol with 20mg piperine	Placebo (silica)	-
Placebo	Trans- resveratrol	-
Placebo	Placebo (silica)	-

Primary Outcome Measures

Name	Time	Method
Modulation of levels of total haemoglobin	80 minutes following treatment administration
Modulation of levels of deoxygenated haemoglobin	80 minutes following treatment administration
Modulation of levels of oxygenated haemoglobin	80 minutes following treatment administration

Secondary Outcome Measures

Name	Time	Method
Number of participants displaying significant modulation of cognitive performance	40-80 minutes post dose	Cognitive performance was assessed at baseline and then again 40 minutes post-treatment to assess if any changes had taken place.

Trial Locations

Locations (1)

Brain performance and nutrition research centre, Northumbria university; 🇬🇧 Newcastle upon Tyne, Tyne and Wear, United Kingdom